Why WHO assessment of safety and efficacy is essential for Covaxin to get nod for global emergency use-Health News , Firstpost

To date, covacin, which has been administered a 77.8% efficacy rate and a dose of at least 2.5 chlores, has been evaluated by WHO as the only indigenous people in India. COVID-19 (New Coronavirus Infection) Vaccines are looking at the emergency use list. Clearing the WHO licensing process will be shot in the arms of the jab, which has dealt with uncertainty and a share of controversy, even if it has become a major component of India.
Vaccination drive.

Why is a meeting with WHO important?

The World Health Organization (WHO) has extended emergency use authorization to a total of seven manufacturers worldwide. Three of these produce the Oxford-AstraZeneca vaccine, and submissions are linked to various national-level regulators. This includes those by the Indian Serum Institute after Covishield was approved by the Drugs Controller General of India (DCGI). Other vaccine manufacturers are Pfizer-BioNtech, Moderna, Janssen (which manufactures single-shot Johnson & Johnson vaccines), and China National Pharmaceutical.

When India provided expedited approval of foreign vaccines for emergency use in India, he said he welcomed the release of vaccines approved for provisional use by WHO in India. Apart from WHO, vaccines approved by US, UK, EU and Japanese regulators were also said to be able to apply for deployment in India. Therefore, it is clear that there is a level of confidence associated with the green light of vaccines from these regulators. Covaxin received an urgent nod from Indian health authorities, but still failed to prevent controversy and uncertainty about its use.

One concern raised by those vaccinated with covacin is whether the lack of approval of the vaccine by international regulators will affect their travel to other countries. Speculation surrounding vaccine passports has raised concerns that countries will not accept vaccine certificates if the jab in question is not approved by international regulators.But countries like the United States say they’re only negative so far, so these fears may be unfounded. COVID-19 (New Coronavirus Infection) Testing is sufficient when boarding an airplane.

More importantly, the WHO nod allows Bharat Biotech to easily bring shots and technology to other countries and manufacturers to expand their use worldwide. According to WHO, its “emergency use list (EUL) is a prerequisite for the supply of Covax Facility vaccines and also allows countries to quickly import and control their own regulatory approvals. COVID-19 (New Coronavirus Infection)
Covax is an international alliance working to ensure a fair vaccine supply to poor countries.

What was the Covaxin approval process in India?

DCGI granted Covaxin an emergency use authorization in January based on Phase 1 and Phase 2 clinical trials. Authorities extended the nod while limiting the use of covacin … in emergencies for the public good as a sufficient precaution in subsequent clinical trial modes after the vaccine recipient was administered. I have been given permission to do so. ” For your safety”

Vaccine trials usually include three phases of a clinical trial before being reviewed for approval. Bharat Biotech announced the interim results of the Phase 3 trial in March of this year, and a few days before the meeting with WHO, the final of the trial of 25,800 people who showed an overall 77.8% efficacy against Covaxin. I shared the data. Phase 3 data are reportedly reviewed by the Subject Expert Committee (SEC), an independent committee that advises the DCGI on issues such as new drug approval.

Recently, US drug regulators have advised Covaxin to seek full approval in the country rather than an urgent nod. This was seen as a setback to the rapid launch of vaccines in the United States. In the United States, it is already seen that there is a sufficient stockpile of vaccines to meet domestic vaccination needs.

What happens at a meeting with WHO?

The June 23 date with Covaxin’s WHO is for a pre-submission meeting, and corporate stakeholders will share the latest clinical trial data with UN Health Organization officials. Company officials reportedly said they would give a detailed presentation and discuss the remaining submissions required by WHO.

In that regard, the pre-submission meeting serves as a step towards submitting pharmaceutical documentation on vaccines for review by WHO experts. A Bharat Biotech official said last month that WHO’s EUL expects to nod between July and September of this year.

In WHO’s own words, “Pre-submission meetings are an important part of the drug evaluation process. Pre-submission meetings provide opportunities for advice and guidance before submitting drug documents, giving applicants the opportunity to meet with WHO. Provide. Drug evaluators involved in product evaluation. “

What does WHO evaluate as part of the EUL process?

According to WHO, EUL is a “procedure for evaluating unlicensed vaccines” that provides other interventions in public health emergencies to make such products readily available to those in need. I will. EUL is associated with public health emergencies and is “based on an assessment of whether an illness can cause an outbreak, epidemic, or pandemic. No product is available.
Illness can be eradicated or prevented … “

For example, with regard to EUL, for vaccines still under development, “WHO evaluates quality, safety, and efficacy data generated during development, conducts risk and benefit assessments, and uses them outside of clinical trials. Determine if you can. ” An important idea is: “In order for a clinical trial vaccine to be considered suitable for use in a public health emergency, the data need to demonstrate that the target population has benefits that outweigh the risks of its use. There is. “

Statistically speaking, WHO states: COVID-19 (New Coronavirus Infection) Vaccines should show at least 50 percent efficacy in mandatory trials. Covaxin has met this requirement with the latest Phase 3 results.

However, WHO points out that EUL is “only a temporary measure to ensure the availability of preventative tools that show a favorable benefit-to-risk ratio” in a public health emergency (PHE). I will. Therefore, WHO states that manufacturers need to “promise to continue development” and “provide detailed guidance and risk management plans” for products that acquire EUL.

How was Covaxin developed?

Vaccines are characterized by being the first indigenous people in India COVID-19 (New Coronavirus Infection) It is a vaccine and was developed by Bharat Biotech in collaboration with the National Institute of Virology (NIV) of the Indian Medical Research Council (ICMR). This vaccine is based on what is known as the “whole virion inactivated Vero cell” platform. Bharat Biotech said the vaccine contains “a dead virus that cannot infect humans but can instruct the immune system to initiate a protective response against the infection.”